Program | 2011 ISMRC | 8th International Symposium on Minimal Residual Cancer

Guidance

Sep 21 (Wed.) 8:30～10:30

Chairpersons :: Dave S. Hoon
John Wayne Cancer Institute, USA; Kiyohiko Hatake
Cancer Chemotherapy Center, JFCR, Tokyo, Japan; Sponsored by Bayer Yakuhin, Ltd.

PL1-1 Micrometastases and circulating tumour cells
Keynote Lecture: Klaus Pantel
Institute of Tumour Biology, Center of Experimental Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany
PL1-2 Ribophorin Ⅱ (RPN2) as a novel therapeutic target for breast cancer stem cells: Takahiro Ochiya
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Japan
PL1-3 Molecular Characterization of Circulating Tumor Cells in breast cancer: Evi Lianidou
University of Athens, Greece
PL1-4 Characterization of CTCs in GI Cancer: Hideo Baba
Graduate School of Medical Sciences, Kumamoto University, Japan

Sep 21 (Wed.) 13:20～15:20

Chairpersons :: Danny R. Welch
Department of Cancer Biology and KU Cancer Center, The University of Kansas Medical Center, USA; Toshiaki Watanabe
Department of Surgery, Teikyo University School of Medicine, Japan; Sponsored by TAIHO PHARMACEUTICAL CO., LTD.

PL2-1 Clinical significance of CTCs and related technology in GI cancers: Kiyohiko Hatake et al.
Department of Medical Oncology, Cancer Institute Hospital, and Division of Clinical Chemotherapy, Cancer Chemotherapy Center, JFCR, Tokyo, Japan
PL2-2 Disseminated and circulating tumor cells detection and characterization in breast cancer: Jean-Yves Pierga
Institut Curie & Universite Paris Descartes, France
PL2-3 Clinical significance of minimal residual cancer in the treatment of breast cancer: Masakazu Toi et al.
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Japan
PL2-4 Clinical significance of circulating tumor cells detection in cancer patients: Hisae Iinuma
Surgery, Teikyo University School of Medicine, Japan

Sep 22 (Thu.) 8:30～10:30

Chairpersons :: Klaus Pantel
University Medical Center Hamburg-Eppendorf, Germany; Kenichi Sugihara
Surgical Oncology, Tokyo Medical & Dental University, Japan; Sponsored by Ortho-Clinical Diagnostics K.K.

PL3-1 Clinical Utility of Pre-Treatment Assessment of CTCs and Genomic Profiling In Early Stage Melanoma Patients.: Dave S. Hoon
John Wayne Cancer Institute, USA
PL3-2 Personalized management of GI cancer based on the status of minimal residual cancer: Yuko Kitagawa et al.
Department of Surgery, Keio University School of Medicine, Tokyo, Japan
PL3-3 Relevance of intraperitoneal free cancer cells in gastric cancer: Yasuhiro Kodera et al.
Department of Surgery Ⅱ, Nagoya University, Japan
PL3-4 Clinical significance of isolated tumor cells in esophageal and gastric cancer: Shoji Natsugoe et al.
Graduate School of Medicine, Kagoshima University, Japan

Sep 22 (Thu.) 13:20～15:20

Chairpersons :: Wolfgang Deppert
Department of Tumor Virology, Heinrich-Pette-Institute, Germany; Hideyuki Saya
Division of Gene Regulation, IAMR, Keio University School of Medicine, Japan

PL4-1 Non-codingRNAs - from scientist bench to patient bedside: George Calin
The University of Texas MD Anderson Cancer Center, USA
PL4-2 A novel molecular basis for establishment of liver metastasis of colorectal cancer cells: Hitoshi Nakagama et al.
National Cancer Center Research Institute, Japan
PL4-3 New molecular Biomarkers of Cancer: miRNAs and Beyond: Muller Fabbri
Ohio State University Comprehensive Cancer Center, USA
PL4-4 Molecular imaging and multidisciplinary therapy for human cancer with telomerasespecific oncolytic adenovirus: Toshiyoshi Fujiwara
Department of Gastroenterological Surgery, Okayama University Graduate School, Japan

Sep 23 (Fri.) 8:30～10:30

Chairpersons :: Hitoshi Nakagama
National Cancer Center Research Institute, Japan; Mitsuo Shimada
Department of Surgery,University of Tokushima, Japan; Sponsored by Eli Lilly Japan K.K.

PL5-1 Tumor cell dissemination and metastasis in a mouse model for oncogene-induced mammary carcinogenesis: Wolfgang Deppert et al.
Department of Tumor Virology, Heinrich-Pette-Institute, Germany
PL5-2 Muse cells: a novel type of adult human pluripotent stem cells that exist in mesenchymal tissues: Mari Dezawa
Graduate School of Medicine, Tohoku University, Japan
PL5-3 Metastasis genetics, epigenetics and the tumor microenvironment: Danny R. Welch
Department of Cancer Biology and KU Cancer Center, The University of Kansas Medical Center, Kansas City, KS, USA
PL5-4 Role of CD44 in cancer stem cells and metastasis: Hideyuki Saya
Division of Gene Regulation, IAMR, Keio University School of Medicine, Japan

Sep 21 (Wed.) 12:00～12:50

Chairperson :: Kosei Hirakawa
Department of Surgical Oncology Graduate School of Medicine Osaka City　University, Japan; Sponsored by Merck Serono Co., Ltd.
Bristol-Myers K.K.

LS-1 Personalized Therapy Brings Innovation to CRC Treatment: Taroh Satoh
Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Japan

Sep 22 (Thu.) 12:00～12:50

Chairperson :: Yuichiro Doki
Department of Gastroenterological Surgery, Osaka University, Graduate School of Medicine, Japan; Sponsored by YAKULT HONSHA CO., LTD.

LS-2 Adjuvant chemotherapy for gastric cancer: Mitsuru Sasako
Department of Surgery, Hyogo College of Medicine, Japan

Sep 21 (Wed.) 18:10～19:10

Chairperson :: Yoshihiko Maehara
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Japan; Sponsored by Sysmex Corporation

ES-1 Clinical use of the OSNA assay for detection of sentinel lymph node metastases in breast cancer patients: Yasuhiro Tamaki
Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Japan
ES-2 Clinical application of molecular biological testing for detecting lymph node metastasis of colorectal cancer: Hirofumi Yamamoto
Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Japan